PT4355306T - Composição em granulado compreendendo nilotinib - Google Patents
Composição em granulado compreendendo nilotinibInfo
- Publication number
- PT4355306T PT4355306T PT227342722T PT22734272T PT4355306T PT 4355306 T PT4355306 T PT 4355306T PT 227342722 T PT227342722 T PT 227342722T PT 22734272 T PT22734272 T PT 22734272T PT 4355306 T PT4355306 T PT 4355306T
- Authority
- PT
- Portugal
- Prior art keywords
- nilotinib
- granulated composition
- granulated
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21180485 | 2021-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4355306T true PT4355306T (pt) | 2026-03-31 |
Family
ID=76532125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT227342722T PT4355306T (pt) | 2021-06-19 | 2022-06-15 | Composição em granulado compreendendo nilotinib |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240316044A1 (pt) |
| EP (1) | EP4355306B1 (pt) |
| AU (1) | AU2022292092A1 (pt) |
| CA (1) | CA3224750A1 (pt) |
| MX (1) | MX2023015480A (pt) |
| PT (1) | PT4355306T (pt) |
| WO (1) | WO2022263510A1 (pt) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| WO2010054056A2 (en) | 2008-11-05 | 2010-05-14 | Teva Pharmaceutical Industries Ltd. | Nilotinib hci crystalline forms |
| IN2011CH01887A (pt) | 2011-06-02 | 2012-12-14 | ||
| AR086913A1 (es) | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| US9567317B2 (en) | 2012-10-19 | 2017-02-14 | Basf Se | Multicomponent crystalline system comprising nilotinib and selected co-crystal formers |
| EP2988729A1 (en) | 2013-04-25 | 2016-03-02 | Sun Pharmaceutical Industries Limited | Pharmaceutical gastro-retentive solid oral dosage form of nilotinib |
| EA036204B1 (ru) | 2015-10-16 | 2020-10-14 | Нобел Илач Санайи Ве Тиджарет А.Ш. | Фармацевтические композиции нилотиниба гидрохлорида |
| EP3429589B1 (en) * | 2016-03-17 | 2022-12-14 | Sun Pharmaceutical Industries Ltd | Pharmaceutical composition of nilotinib |
| CZ2016785A3 (cs) * | 2016-12-09 | 2018-06-20 | Zentiva, K.S. | Farmaceutická kompozice obsahující nilotinib a způsob její přípravy |
| CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
| US12065426B2 (en) | 2018-11-05 | 2024-08-20 | Laurus Labs Limited | Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same |
-
2022
- 2022-06-15 MX MX2023015480A patent/MX2023015480A/es unknown
- 2022-06-15 EP EP22734272.2A patent/EP4355306B1/en active Active
- 2022-06-15 WO PCT/EP2022/066305 patent/WO2022263510A1/en not_active Ceased
- 2022-06-15 CA CA3224750A patent/CA3224750A1/en active Pending
- 2022-06-15 US US18/571,942 patent/US20240316044A1/en active Pending
- 2022-06-15 PT PT227342722T patent/PT4355306T/pt unknown
- 2022-06-15 AU AU2022292092A patent/AU2022292092A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4355306B1 (en) | 2026-01-21 |
| AU2022292092A1 (en) | 2024-02-01 |
| EP4355306A1 (en) | 2024-04-24 |
| MX2023015480A (es) | 2024-01-19 |
| WO2022263510A1 (en) | 2022-12-22 |
| CA3224750A1 (en) | 2022-12-22 |
| US20240316044A1 (en) | 2024-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4227390A4 (en) | COMPOSITION CONTAINING A REFRIGERANT FLUID | |
| EP4148096A4 (en) | COMPOSITION | |
| EP4094582A4 (en) | COMPOSITION | |
| EP4328279A4 (en) | COMPOSITION | |
| EP4115893A4 (en) | Anti-tumor composition | |
| EP4279545A4 (en) | COMPOSITION | |
| EP4352194C0 (en) | COMPOSITION OF TABLET | |
| EP3871694A4 (en) | COMPOSITION | |
| EP4313320A4 (en) | ANTIPERSPIRANT COMPOSITION | |
| EP3981256A4 (en) | COMPOSITION | |
| EP3630113A4 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR | |
| EP3941942A4 (en) | COMPOSITION | |
| DK3908321T3 (da) | Farmaceutisk sammensætning | |
| EP3954721A4 (en) | Composition | |
| EP3914303C0 (en) | VIRUCIDAL COMPOSITION | |
| EP3741814C0 (en) | COMPOSITION | |
| EP4372077A4 (en) | AUTOPHAGY-ACTIVATING COMPOSITION | |
| EP4337752C0 (en) | COMPOSITION | |
| EP4330366C0 (en) | COMPOSITION | |
| EP4353086A4 (en) | Sweetener composition | |
| EP4256012C0 (en) | COMPOSITION | |
| EP4291042C0 (en) | COMPOSITION DERIVED FROM OATS | |
| PT3949952T (pt) | Composição farmacêutica | |
| EP4038129A4 (en) | INSECT REPELLENT COMPOSITION | |
| PT4355306T (pt) | Composição em granulado compreendendo nilotinib |